Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 3-(3-cyano-4-carboxymethyl-5-carboxy-2-thienyl)-3-azapentanedioic Distrontium Salt
2. Protelos
3. S 12911
4. S-12911
5. S12911
6. S12911-0
7. S12911-2
8. S12911-5
9. Strontium Ranelate
1. Distrontium Renelate Octahydrate
2. 674773-15-0
3. 8pd4806e06
4. Strontium Ranelate
5. 3-thiopheneacetic Acid, 5-(bis(carboxymethyl)amino)-2-carboxy-4-cyano-, Strontium Salt (1:2), Octahydrate
6. Unii-8pd4806e06
7. Dtxsid00217833
8. Q27270857
| Molecular Weight | 657.6 g/mol |
|---|---|
| Molecular Formula | C12H22N2O16SSr2 |
| Hydrogen Bond Donor Count | 8 |
| Hydrogen Bond Acceptor Count | 19 |
| Rotatable Bond Count | 4 |
| Exact Mass | 657.8802283 g/mol |
| Monoisotopic Mass | 657.8802283 g/mol |
| Topological Polar Surface Area | 224 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 533 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 11 |
Bone Density Conservation Agents
Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS. (See all compounds classified as Bone Density Conservation Agents.)
ABOUT THIS PAGE
A Distrontium Renelate Octahydrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Distrontium Renelate Octahydrate, including repackagers and relabelers. The FDA regulates Distrontium Renelate Octahydrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Distrontium Renelate Octahydrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Distrontium Renelate Octahydrate supplier is an individual or a company that provides Distrontium Renelate Octahydrate active pharmaceutical ingredient (API) or Distrontium Renelate Octahydrate finished formulations upon request. The Distrontium Renelate Octahydrate suppliers may include Distrontium Renelate Octahydrate API manufacturers, exporters, distributors and traders.
click here to find a list of Distrontium Renelate Octahydrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Distrontium Renelate Octahydrate written confirmation (Distrontium Renelate Octahydrate WC) is an official document issued by a regulatory agency to a Distrontium Renelate Octahydrate manufacturer, verifying that the manufacturing facility of a Distrontium Renelate Octahydrate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Distrontium Renelate Octahydrate APIs or Distrontium Renelate Octahydrate finished pharmaceutical products to another nation, regulatory agencies frequently require a Distrontium Renelate Octahydrate WC (written confirmation) as part of the regulatory process.
click here to find a list of Distrontium Renelate Octahydrate suppliers with Written Confirmation (WC) on PharmaCompass.
Distrontium Renelate Octahydrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Distrontium Renelate Octahydrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Distrontium Renelate Octahydrate GMP manufacturer or Distrontium Renelate Octahydrate GMP API supplier for your needs.
A Distrontium Renelate Octahydrate CoA (Certificate of Analysis) is a formal document that attests to Distrontium Renelate Octahydrate's compliance with Distrontium Renelate Octahydrate specifications and serves as a tool for batch-level quality control.
Distrontium Renelate Octahydrate CoA mostly includes findings from lab analyses of a specific batch. For each Distrontium Renelate Octahydrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Distrontium Renelate Octahydrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Distrontium Renelate Octahydrate EP), Distrontium Renelate Octahydrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Distrontium Renelate Octahydrate USP).
LOOKING FOR A SUPPLIER?
